Alleging a "course of anticompetitive conduct," the Federal Trade Commission filed a complaint against Cephalon Inc. regarding deals signed two years ago between the firm and four generic manufacturers to keep lower-cost generic versions of its flagship narcolepsy drug, Provigil, from reaching the market until 2012. (BioWorld Today) Read More
